Introduction
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market was valued at USD XX Billion in 2019 and is projected to reach USD XX billion by 2025, at a CAGR of XX% from 2020-2025. Non-alcoholic Steatohepatitis is an advanced stage of non-alcoholic fatty liver disease. Increasing prevalence of chronic liver condition, growing research & development activities are fueling the market growth. Additionally, increasing geriatric population, rising incidences of obesity, type 2 diabetes, awareness about diagnostic tools, government focus on healthcare facilities, are also major driving factors for the Non-alcoholic Steatohepatitis (NASH) Biomarkers Market.
On the other hand, limited accuracy of NASH diagnostic tools, such as biomarkers in proper diagnosis, are some of the restraining factor this Market.
Geographical Overview
At a global level, the North America region was holding the highest market share in 2019, due to presence of key players, growing incidences of NASH disease, technological advancements. Whereas, Asia Pacific region is considered the fastest-growing region with key players adopting expansion strategy in this region to gain maximum market share in the coming years. Key factors such as growth in diagnostic techniques, increasing prevalence of NASH, developing healthcare infrastructure are driving Non-alcoholic Steatohepatitis (NASH) Biomarkers Market in the Asia Pacific region.
?
Segmental Overview
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market is segmented as per below specifications -
By Marker Type:
• Serum Biomarkers
• Hepatic Fibrosis Biomarkers
• Apoptosis Biomarkers
• Oxidative
By End User:
• Contract Research Organization (CRO)
• Pharmaceutical Industry
• Academic Research Institute
• Hospitals
• Diagnostic Laboratories
Competitor Analysis
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market has presence of some of the key major players across globe which includes
• Novartis AG
• Shire PLC
• Allergan PLC (Tobira Therapeutics)
• Cadila Healthcare Limited
• Conatus Pharmaceuticals Inc.
• Galmed Pharmaceuticals Ltd.
• Gemphire Therapeutics Inc.
• Genfit SA
• Gilead Sciences Inc.
• Intercept Pharmaceuticals Inc.
These key players are concentrating its efforts on the continuous product improvement with innovative initiatives to have an edge over other competitors. Further, to garner maximum market share, companies are adopting merger/ acquisition/ partnership and maintaining strong distribution networks strategies.
By Geographical Locations:
• North America
o U.S.
o Canada
• Europe
o U.K.
o France
o Italy
o Germany
o Spain
o Russia & CIS
o Rest of Europe
• Asia-Pacific
o China
o India
o Japan
o South Korea
o ASEAN
o Rest of Asia Pacific
• Latin America
o Brazil
o Argentina
o Rest of LATAM
• Middle East & Africa
o UAE
o South Africa
o Rest of MEA
Highlights of the report
What is Non-alcoholic Steatohepatitis (NASH) Biomarkers Market?
Who all are key market players in the industry?
How the Parent Industry is growing?
Where are the key opportunities for new market entrant?
A comprehensive analysis, which covers key growth factors across the value chain
Recent developments in market
Granular Market Segmentation
Market size projection based on Historical & current market trends
Market share analysis and key strategies adopted by leading players
Production Cost & Sensitivity Analysis
Country Level Market Analysis of Top 16 countries
Data Driven Decision Recommendations
Chapter 1 Research Objective
1.1 Need of the Research Report
1.2 Client Objectives
1.3 Offered Solutions
Chapter 2 Recommendations
2.1 Executive Summary
2.1.1 Market Overview
2.1.2 Competitive Insights
2.1.3 Segmental Analysis
2.1.4 Geographical Market Details
2.2 Lead Generation
2.3 Consultant
2.4 Return on Investment
Chapter 3 Research Methodology
3.1 Chromatus Database
3.2 Paid Sources
3.3 Primary Data Collection
3.3.1 Email Surveys
3.3.2 Telephonic Interviews
3.3.3 Face to Face Interviews
3.4 Secondary Data Collection
3.4.1 Annual Reports
3.4.2 Government Publications
3.4.3 Trade Data
3.4.4 Association Data
3.4.5 Research Papers/ Blogs/ News Articles
3.5 Expert Advisory Panel
3.6 Data Analytics Model
Chapter 4 Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Overview
4.1 Parent Market Overview
4.2 Patent Analysis
4.3 PESTEL Analysis
4.3.1 Political
4.3.2 Economical
4.3.3 Social
4.3.4 Technological
4.3.5 Legal
4.4 SWOT Analysis
4.4.1 Strengths
4.4.2 Weakness
4.4.3 Opportunities
4.4.4 Threats
4.5 Regulations
4.6 Value Chain/ Supply Chain Analysis
4.7 Procurement & Vendor Analysis
4.8 Porters Five Analysis
4.8.1 Threat of new entrants
4.8.2 Bargaining power of suppliers
4.8.3 Bargaining power of buyers
4.8.4 Threat of substitutes
4.8.5 Competitive rivalry
Chapter 5 Regional Analysis
Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Estimation and Forecast, 2019 - 2025 (USD Billion)
5.1 North America Market
5.1.1 U.S.
5.1.1 Canada
5.2 Europe Market
5.2.1 UK
5.2.2 Germany
5.2.3 France
5.2.4 Spain
5.2.5 Italy
5.2.6 Russia & CIS
5.2.7 Rest of Europe
5.3 Asia Pacific Market
5.3.1 China
5.3.2 Japan
5.3.3 India
5.3.4 South Korea
5.3.5 ASEAN
5.3.6 Rest of Asia Pacific
5.4 Rest of the World
5.4.1 Latin America
5.4.1.1 Brazil
5.4.1.2 Argentina
5.4.1.3 Rest of Latin America
5.4.2 Middle East
5.4.3 Africa
Chapter 6 Company Profile
6.1 Novartis AG
6.1.1 Introduction
6.1.2 Financial Overview
6.1.3 Product Portfolio
6.1.4 Recent Developments
6.1.5 SWOT Analysis
6.2 Shire PLC
6.3 Allergan PLC (Tobira Therapeutics)
6.4 Cadila Healthcare Limited
6.5 Conatus Pharmaceuticals Inc.
6.6 Galmed Pharmaceuticals Ltd.
6.7 Gemphire Therapeutics Inc.
6.8 Genfit SA
6.9 Gilead Sciences Inc.
6.10 Intercept Pharmaceuticals Inc.
Chapter 7 Competitor Analysis
7.1 Company Ranking
7.2 Key Innovators
7.3 Market Leader
7.4 Emerging Players
7.5 Strategic Alliances
7.6 Competitive Matrix of 10 Companies
Chapter 8 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by Marker Type Estimation and Forecast, 2019 - 2025 (USD Billion)
8.1 Serum Biomarkers
8.2 Hepatic Fibrosis Biomarkers
8.3 Apoptosis Biomarkers
8.4 Oxidative
Chapter 9 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by End User Type Estimation and Forecast, 2019 - 2025 (USD Billion)
9.1 Contract Research Organization (CRO)
9.2 Pharmaceutical Industry
9.3 Academic Research Institute
9.4 Hospitals
9.5 Diagnostic Laboratories
Chapter 10 Appendix
10.1 Data Sources
10.2 Abbreviations
10.3 About US
10.4 Disclaimer
10.5 Key Notes
List of Tables
Table 1 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, by Region, 2019 - 2025 (USD Billion)
Table 2 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, by Marker Type, 2019 - 2025 (USD Billion)
Table 3 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, by End User Type, 2019 - 2025 (USD Billion)
Table 4 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, by Distribution Type, 2019 - 2025 (USD Billion)
Table 5 North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 6 North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by Marker Type 2019 - 2025 (USD Billion)
Table 7 North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by End User Type 2019 - 2025 (USD Billion)
Table 8 North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by Distribution Type 2019 - 2025 (USD Billion)
Table 9 US Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 10 Canada Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 11 Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 12 Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by Marker Type 2019 - 2025 (USD Billion)
Table 13 Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by End User Type 2019 - 2025 (USD Billion)
Table 14 Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by Distribution Type 2019 - 2025 (USD Billion)
Table 15 UK Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 16 Germany Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 17 France Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 18 Spain Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 19 Italy Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 20 Russia & CIS Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 21 Rest of Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 22 Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 23 Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by Marker Type 2019 - 2025 (USD Billion)
Table 24 Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by End User Type 2019 - 2025 (USD Billion)
Table 25 Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by Distribution Type 2019 - 2025 (USD Billion)
Table 26 China Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 27 Japan Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 28 India Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 29 South Korea Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 30 ASEAN Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 31 Rest of Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 32 Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 33 Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by Marker Type 2019 - 2025 (USD Billion)
Table 34 Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by End User Type 2019 - 2025 (USD Billion)
Table 35 Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by Distribution Type 2019 - 2025 (USD Billion)
Table 36 Brazil Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 37 Argentina Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 38 Rest of Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 39 Middle East Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 40 Middle East Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by Marker Type 2019 - 2025 (USD Billion)
Table 41 Middle East Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by End User Type 2019 - 2025 (USD Billion)
Table 42 Middle East Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by Distribution Type 2019 - 2025 (USD Billion)
Table 43 Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 2019 - 2025 (USD Billion)
Table 44 Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by Marker Type 2019 - 2025 (USD Billion)
Table 45 Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by End User Type 2019 - 2025 (USD Billion)
Table 46 Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market by Distribution Type 2019 - 2025 (USD Billion)
List of Figures
Fig. 1 Primary Research Method
Fig. 2 Secondary Research Method
Fig. 3 Value chain analysis
Fig. 4 PESTEL Analysis
Fig. 5 SWOT Analysis
Fig. 6 Porters Five forces analysis
Fig. 7 Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Penetration & growth prospect mapping
Fig. 8 Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Competitive snapshot
Fig. 9 Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Segmental snapshot
Fig. 10 Market Overview
Fig. 11 Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Product Analysis, 2019 - 2025
Fig. 12 Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Regional Analysis, 2019 - 2025
Fig. 13 Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Competitive Matrix
Fig. 14 Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Revenue Mix